Freenome Raises $254M to Accelerate Early Cancer Detection Platform
Freenome, a leader in blood-based early cancer detection, has raised $254M, fueled by its innovative multiomics platform
Eventide Asset Management Bain Capital Life Sciences Life Sciences Growth Fund Quest Diagnostics American Cancer Society Brightedge Ventures Freenome Raises
Source: hitconsultant.net